NSAID Use May Affect Axial Spondyloarthritis Diagnosis via MRI
Findings suggest that patients with suspected axial spondyloarthropathy not taking NSAIDs were more likely to have MRI proven inflammation compared with patients taking NSAIDs.
Patients with suspected axial spondyloarthropathy (AxSpA) not taking non-steroidal anti-inflammatory drugs (NSAIDs) are more likely to have MRI proven inflammation compared with those taking NSAIDs, according to study results presented at the Radiological Society of North America (RSNA) 2021 Annual Meeting.
“Undiagnosed AxSpA can have significant impact on patients’ physical and mental health but also their quality of life and livelihood,” the authors wrote. “It is possible that NSAID use at the time of scanning reduces the diagnostic yield of MRI scanning.”
The findings were presented by Prasanna Partha Sarathy, MBChB, BMedSc, of Singleton Hospital in Swansea, UK.
Early AxSpA diagnosis, which depends on HLA-B27 testing and MRI imaging, is essential. While NSAIDs can lead to improvement in MRI appearances, patients suspected of having AxSpA are often prescribed these drugs for symptomatic relief before imaging. In this study, the researchers assessed the use of MRI in patients with suspected AxSpA and the effect of NSAIDs on the diagnostic yield of MRI scanning.
The six-month, multicenter, retrospective cohort study included 74 patients referred for MRI of the spine for suspected AxSpA. At the time of MRI, the patients were asked about NSAID use. The MRI results were assessed for evidence of active inflammation.
MRI showed signs of AxSpA in 22% of the patients. Those not using NSAIDs at the time of the scan were more likely to have MRI proven inflammation (P = .017). After adjusting for age and gender, the study found that patients not taking NSAIDs were more likely to have MRI proven inflammation compared with those taking NSAIDs (OR 8.3; 95% CI, 1.9-36; P = .005). This finding was mainly driven by the no NSAID versus regular NSAID use subgroups (OR 14; 95% CI, 2.1-97; P = .006). No difference was seen between patients not taking NSAIDs and those taking NSAIDs as required, or between patients taking NSAIDs as required versus those taking regular NSAIDs.
“This study suggests suspected AxSpA patients not taking NSAIDs were more likely to have MRI proven inflammation compared to patients taking NSAIDs especially those on regular NSAIDs,” the authors wrote.
They suggested that more prospective research is needed to explore this relationship further.
For more coverage of RSNA 2021, click here.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
Chest CT Study Shows Higher Emphysema Risk from Combination of Marijuana and Cigarette Smoking
November 28th 2023People who smoke marijuana and cigarettes have 12 times the risk for centrilobular emphysema than non-smokers, according to new computed tomography (CT) research presented at the annual Radiological Society of North America (RSNA) conference.
Study: Black Patients Less Likely Than Others to Receive MRI Assessment of Cognitive Impairment
November 27th 2023In a four-year study of over 1,600 patients who had outpatient head CTs, head CT angiography and/or brain MRI to assess cognitive impairment, researchers found that Black patients were over 9 percent less likely than White patients and over 16 percent less likely than Hispanic patients to receive brain MRI.
Study Shows Benefits of AI in Detecting Lung Cancer Risk in Non-Smokers
November 22nd 2023Artificial intelligence (AI) assessments of chest X-rays identified 28 percent of a 17,000 plus cohort of never-smokers as being at high-risk for lung cancer, according to research to be presented at the annual Radiological Society of North America (RSNA) conference next week.
